Clinical Trial

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology…

1 year ago

Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication

Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and…

1 year ago

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases…

1 year ago

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to…

1 year ago

BioNTX Names Osteal Therapeutics 2023 Rising Star

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award…

1 year ago

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled…

1 year ago

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be…

1 year ago

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a…

1 year ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based…

1 year ago

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in…

1 year ago